Zolbetuximab improves survival in patients with advanced or metastatic gastric adenocarcinoma
1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...
1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free
Then $49.90/year.
Already a member? Sign in